ストックスクリーナーアプリを入手
460.87
0.92%
4.18
アフターアワーズ：
482.46
21.59
+4.68%
前日終値:
$456.69
開ける：
$455.59
24時間の取引高:
1.16M
Relative Volume:
0.82
時価総額：
$117.08B
収益：
$12.07B
当期純損益:
$3.95B
株価収益率:
30.05
EPS:
15.3349
ネットキャッシュフロー:
$3.19B
1週間 パフォーマンス:
-5.18%
1か月 パフォーマンス:
-2.12%
6か月 パフォーマンス:
+16.24%
1年 パフォーマンス:
-5.62%
1日の値動き範囲:
$450.78
$461.26
1週間の範囲:
$450.67
$484.10
52週間の値動き範囲:
$362.50
$519.68
Vertex Pharmaceuticals Inc Stock (VRTX) Company Profile
名前
Vertex Pharmaceuticals Inc
セクター
電話
(617) 341-6393
住所
50 NORTHERN AVENUE, BOSTON, MA
Compare VRTX vs REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
VRTX
Vertex Pharmaceuticals Inc
|
460.87 | 116.01B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
781.60 | 80.33B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
740.40 | 44.42B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
323.59 | 42.53B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
302.29 | 33.32B | 5.36B | 287.73M | 924.18M | 2.5229 |
Vertex Pharmaceuticals Inc Stock (VRTX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-02-13 | アップグレード | Oppenheimer | Perform → Outperform |
| 2026-01-28 | 再開されました | Barclays | Overweight |
| 2026-01-22 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
| 2026-01-12 | アップグレード | Bernstein | Mkt Perform → Outperform |
| 2026-01-07 | 再開されました | UBS | Buy |
| 2026-01-06 | アップグレード | Wolfe Research | Peer Perform → Outperform |
| 2025-12-03 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2025-11-13 | 開始されました | Scotiabank | Sector Outperform |
| 2025-09-25 | アップグレード | Leerink Partners | Market Perform → Outperform |
| 2025-09-03 | 開始されました | Raymond James | Mkt Perform |
| 2025-08-06 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2025-05-07 | ダウングレード | Wolfe Research | Outperform → Peer Perform |
| 2025-05-06 | ダウングレード | Leerink Partners | Outperform → Market Perform |
| 2025-04-22 | 再開されました | Cantor Fitzgerald | Overweight |
| 2025-02-12 | アップグレード | Canaccord Genuity | Sell → Hold |
| 2025-02-11 | アップグレード | Canaccord Genuity | Sell → Hold |
| 2025-01-30 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2024-12-20 | 繰り返されました | H.C. Wainwright | Buy |
| 2024-12-19 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2024-12-09 | アップグレード | Jefferies | Hold → Buy |
| 2024-11-14 | 開始されました | Citigroup | Buy |
| 2024-10-16 | 開始されました | Scotiabank | Sector Perform |
| 2024-10-10 | 再開されました | Raymond James | Mkt Perform |
| 2024-08-05 | ダウングレード | Barclays | Overweight → Equal Weight |
| 2024-06-27 | 開始されました | Redburn Atlantic | Buy |
| 2024-04-11 | アップグレード | Evercore ISI | In-line → Outperform |
| 2024-02-15 | 開始されました | Wolfe Research | Outperform |
| 2024-02-06 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2024-02-02 | ダウングレード | Bernstein | Outperform → Mkt Perform |
| 2024-01-31 | ダウングレード | Maxim Group | Buy → Hold |
| 2024-01-31 | ダウングレード | Robert W. Baird | Neutral → Underperform |
| 2024-01-24 | ダウングレード | Canaccord Genuity | Hold → Sell |
| 2023-12-14 | 繰り返されました | RBC Capital Mkts | Sector Perform |
| 2023-05-30 | 開始されました | William Blair | Outperform |
| 2023-05-04 | 再開されました | Piper Sandler | Overweight |
| 2023-03-21 | 開始されました | Bernstein | Outperform |
| 2023-01-18 | 開始されました | Canaccord Genuity | Hold |
| 2023-01-17 | アップグレード | SVB Leerink | Mkt Perform → Outperform |
| 2022-12-19 | ダウングレード | Jefferies | Buy → Hold |
| 2022-07-13 | 開始されました | Cantor Fitzgerald | Overweight |
| 2022-06-01 | アップグレード | Maxim Group | Hold → Buy |
| 2022-05-23 | 開始されました | SVB Leerink | Mkt Perform |
| 2022-05-06 | ダウングレード | Robert W. Baird | Outperform → Neutral |
| 2022-05-03 | アップグレード | Morgan Stanley | Underweight → Equal-Weight |
| 2022-02-03 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-01-27 | 繰り返されました | JP Morgan | Overweight |
| 2022-01-27 | 繰り返されました | Morgan Stanley | Underweight |
| 2022-01-27 | 繰り返されました | RBC Capital Mkts | Outperform |
| 2022-01-27 | 繰り返されました | Stifel | Hold |
| 2022-01-27 | 繰り返されました | Wolfe Research | Outperform |
| 2022-01-20 | アップグレード | BMO Capital Markets | Market Perform → Outperform |
| 2021-12-09 | 開始されました | Wells Fargo | Overweight |
| 2021-11-19 | 開始されました | BMO Capital Markets | Market Perform |
| 2021-11-19 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2021-09-09 | ダウングレード | Stifel | Buy → Hold |
| 2021-09-07 | ダウングレード | Morgan Stanley | Equal-Weight → Underweight |
| 2021-07-20 | ダウングレード | SVB Leerink | Mkt Perform → Underperform |
| 2021-07-19 | 再開されました | Wolfe Research | Outperform |
| 2021-07-01 | 開始されました | Raymond James | Mkt Perform |
| 2021-06-11 | ダウングレード | Daiwa Securities | Outperform → Neutral |
| 2021-02-23 | アップグレード | Robert W. Baird | Neutral → Outperform |
| 2021-02-02 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-12-30 | 開始されました | Daiwa Securities | Outperform |
| 2020-11-30 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
| 2020-11-20 | 開始されました | Bernstein | Outperform |
| 2020-10-28 | 開始されました | UBS | Buy |
| 2020-07-31 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-07-08 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2020-04-30 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-04-28 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-03-04 | 開始されました | Barclays | Overweight |
| 2020-01-31 | ダウングレード | Robert W. Baird | Outperform → Neutral |
| 2019-11-19 | アップグレード | Guggenheim | Neutral → Buy |
| 2019-11-12 | 開始されました | SunTrust | Buy |
| 2019-10-17 | 再開されました | BofA/Merrill | Buy |
| 2019-09-03 | アップグレード | Goldman | Neutral → Buy |
| 2019-08-01 | ダウングレード | Needham | Buy → Hold |
| 2019-05-23 | 再開されました | Citigroup | Buy |
| 2019-05-21 | 開始されました | Credit Suisse | Outperform |
| 2019-04-12 | 開始されました | Evercore ISI | In-line |
| 2019-03-26 | アップグレード | William Blair | Mkt Perform → Outperform |
| 2019-03-19 | ダウングレード | SVB Leerink | Outperform → Mkt Perform |
| 2019-02-06 | ダウングレード | Maxim Group | Buy → Hold |
すべてを表示
Vertex Pharmaceuticals Inc (VRTX) 最新ニュース
Vertex’s kidney disease drug meets main goal in late-stage trial - WNWN-FM
Vertex Pharmaceuticals (VRTX) Surges 7% Following Promising Tria - GuruFocus
Wolfe Research reiterates Vertex stock rating on IgAN trial data - Investing.com
Vertex Pops On 'Remarkable' Late-Stage Results - Investor's Business Daily
Vertex kidney disease drug hits mark in late-stage study - BioPharma Dive
Vertex says its drug successfully reduced marker of kidney disease in late-stage trial - statnews.com
Vertex jumps after positive Phase 3 interim data for povetacicept in IgA nephropathy - Quiver Quantitative
Vertex Rises After Kidney Drug Meets Goal in Late-Stage Trial - Bloomberg.com
Vertex Pharmaceuticals (VRTX) Reports Positive Phase 3 Trial Res - GuruFocus
After-hours movers: Hewlett Packard Enterprise, Yext, Vertex Pharma By Investing.com - Investing.com Canada
After-hours movers: Hewlett Packard Enterprise, Yext, Vertex Pharma - Investing.com
Vertex Pharmaceuticals Stock Jumps After The Close: Here's Why - Benzinga
Vertex's kidney disease drug meets main goal in late-stage trial - AOL.com
Vertex to seek US approval after promising late-stage results for kidney drug - Reuters
Is A Vertex Buyout Of Crispr Therapeutics Inevitable? Here's My Take (NASDAQ:CRSP) - Seeking Alpha
Experimental kidney drug slashes protein in urine in major Vertex trial - Stock Titan
Buying This 1 Biotech Stock Now Could Help Make You a Multimillionaire Retiree - The Motley Fool
Prevail Innovative Wealth Advisors Boosts Vertex Pharmaceuticals Stake - National Today
2,440 Shares in Vertex Pharmaceuticals Incorporated $VRTX Purchased by Legacy Capital Group California Inc. - MarketBeat
Neo Ivy Capital Management Purchases New Position in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Cresset Asset Management LLC Decreases Stock Position in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Insider Sell: Duncan Mckechnie Sells Shares of Vertex Pharmaceuticals Inc (VRTX) - GuruFocus
Vertex presents new Phase IV data on Journavx - The Pharma Letter
Quantbot Technologies LP Buys $1.46M Stake in Vertex Pharmaceuticals - National Today
Quantbot Technologies LP Takes $1.46 Million Position in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Dimensional Fund Advisors Increases Vertex Pharmaceuticals Stake - National Today
Dimensional Fund Advisors LP Purchases 187,359 Shares of Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Vertex to Participate in Upcoming March Investor Conferences - Business Wire
Vertex Pharmaceuticals to Present Data on JOURNAVX® for Pain Management After Aesthetic and Reconstructive Surgeries - geneonline.com
Did Vertex’s (VRTX) Earnings Beat and Advancing Pipeline Just Shift Its Investment Narrative? - Yahoo Finance
Vertex Pharmaceuticals Incorporated Presents New Data on JOURNAVX for Effective Pain Management Following Aesthetic and Reconstructive Procedures - marketscreener.com
Vertex Pharmaceuticals (VRTX) Reports Positive Phase 4 Study Res - GuruFocus
That Demonstrates Effective Pain Management Following Aesthetic and Reconstructive Procedures - Business Wire
2 Biotech Giants to Buy in 2026 - AOL.com
South Dakota Investment Council Cuts Stake in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
2 Biotech Giants to Buy in 2026 - The Motley Fool
CI Investments Inc. Trims Stock Position in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Vertex Pharmaceuticals Hits Day High with Strong 3.48% Intraday Surge - Markets Mojo
Insider Sell: Joy Liu Sells Shares of Vertex Pharmaceuticals Inc (VRTX) - GuruFocus
Is Vertex Pharmaceuticals (VRTX) Still Attractively Priced After Its Multi Year Share Price Run? - simplywall.st
Global Orphan Drugs Market is Anticipated to Cross USD 350 Billion by 2032 | DelveInsight - Bolsamania
Forget CRISPR Therapeutics: This Gene‑Editing Player Already Boasts the Profits It Dreams Of - The Motley Fool
Director files Form 144 to sell shares (NASDAQ: VRTX) - Stock Titan
Teachers Retirement System of Kentucky Reduces Vertex Pharmaceuticals Stake - National Today
Teachers Retirement System of The State of Kentucky Decreases Stake in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
William Blair Investment Management LLC Decreases Stake in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
The Zacks Analyst Blog Highlights Broadcom, AT&T, Vertex and InterGroup - Zacks Investment Research
Top Research Reports for Broadcom, AT&T & Vertex Pharmaceuticals - Yahoo Finance
Vertex Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Vertex Pharmaceuticals Executive Sells Shares - TradingView
Vertex (VRTX) CMO Carmen Bozic executes Rule 10b5-1 sale of 2,329 shares - Stock Titan
Vertex Pharmaceuticals Inc (VRTX) 財務データ
収益
当期純利益
現金流量
EPS
2.86%
大文字化:
|
ボリューム (24 時間):